413 related articles for article (PubMed ID: 34057835)
1. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients.
Chen Y; Xiang Q; Liu L
J Int Med Res; 2021 May; 49(5):3000605211019661. PubMed ID: 34057835
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactivity between piperacillin-tazobactam and cefoperazone-sulbactam in drug-induced immune thrombocytopenia.
He X; Huang W; Wan X; Li X; Chang Q; Ding L
J Int Med Res; 2023 Mar; 51(3):3000605231162434. PubMed ID: 36967671
[TBL] [Abstract][Full Text] [Related]
3. The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia.
Lai CC; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Tu CY; Cheng WC; Chen CH
Medicine (Baltimore); 2023 Jul; 102(28):e34284. PubMed ID: 37443505
[TBL] [Abstract][Full Text] [Related]
4. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
5. The effect of cefoperazone sulbactam and piperacillin tazobactam on mortality in Gram-negative nosocomial infections.
Guclu E; Kaya G; Ogutlu A; Karabay O
J Chemother; 2020 May; 32(3):118-123. PubMed ID: 32096456
[TBL] [Abstract][Full Text] [Related]
6. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.
Karaman S; Vural S; Yildirmak Y; Emecen M; Erdem E; Kebudi R
Pediatr Blood Cancer; 2012 Apr; 58(4):579-83. PubMed ID: 21674768
[TBL] [Abstract][Full Text] [Related]
7. Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia.
Chen CH; Tu CY; Chen WC; Kuo LK; Wang YT; Fu PK; Ku SC; Fang WF; Chen CM; Lai CC
Infect Drug Resist; 2021; 14():2251-2258. PubMed ID: 34168466
[TBL] [Abstract][Full Text] [Related]
8. Comparison of in vitro activities of ceftazidime, piperacillin-tazobactam, and cefoperazone-sulbactam, and the implication on empirical therapy in patients with cancer.
Prabhash K; Medhekar A; Biswas S; Kurkure P; Nair R; Kelkar R
Indian J Cancer; 2009; 46(4):318-22. PubMed ID: 19749462
[TBL] [Abstract][Full Text] [Related]
9. [Effect of β-lactamase detection on reducing the incidence of antibiotic-associated diarrhea in children with severe bacterial pneumonia].
Xiang Y; Wang ZH; Cai P; Zhang Z
Zhongguo Dang Dai Er Ke Za Zhi; 2016 Oct; 18(10):1001-1004. PubMed ID: 27751220
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates: A single-centre study in Zhejiang Province, China.
Hua CZ; Wang HJ; Zhang Z; Tao XF; Li JP; Mi YM; Tang LF; Chen ZM
J Glob Antimicrob Resist; 2019 Sep; 18():47-51. PubMed ID: 30710647
[TBL] [Abstract][Full Text] [Related]
11. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
Nomura S; Hanaki H; Nagayama A
J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
[TBL] [Abstract][Full Text] [Related]
12. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness of cefoperazone-sulbactam vs. piperacillin-tazobactam for the treatment of pneumonia in elderly patients.
Huang CT; Chen CH; Chen WC; Wang YT; Lai CC; Fu PK; Kuo LK; Chen CM; Fang WF; Tu CY; Ku SC
Int J Antimicrob Agents; 2022 Jan; 59(1):106491. PubMed ID: 34871744
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
Aynioglu A; Mutlu B; Hacihanefioglu A
Rev Esp Quimioter; 2016 Apr; 29(2):69-75. PubMed ID: 26888338
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
16. Interaction between caspofungin or voriconazole and cefoperazone-sulbactam or piperacillin-tazobactam by in vitro and in vivo methods.
Keçeli SA; Willke A; Tamer GS; Boral OB; Sonmez N; Cağatay P
APMIS; 2014 May; 122(5):412-7. PubMed ID: 24033828
[TBL] [Abstract][Full Text] [Related]
17. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin vs. Vancomycin/Piperacillin-Tazobactam-Associated Acute Kidney Injury in Noncritically Ill Patients at a Tertiary Care Military Treatment Facility.
Anderson CW; Cazares KS; Lustik MB; Patel SM; Denunzio TM
Mil Med; 2017 Sep; 182(9):e1773-e1778. PubMed ID: 28885936
[TBL] [Abstract][Full Text] [Related]
19. A Non-inferiority Pilot Study Comparing the Clinical Efficacy and Safety of Generic Wide-spectrum Antibiotic Use in Septic Oncology Patients.
Araya I; Fasce G; Núñez E; Opazo JL; Saez E; Hurtado V; Contreras S; Quiñones LA
Drug Res (Stuttg); 2015 Dec; 65(12):635-9. PubMed ID: 25811220
[TBL] [Abstract][Full Text] [Related]
20. Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
Patankar M; Sukumaran S; Chhibba A; Nayak U; Sequeira L
J Assoc Physicians India; 2012 Nov; 60():22-4. PubMed ID: 23767198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]